Dyadic Applied BioSolutions entered into an OEM distribution agreement with Integrated Biotherapeutics, LLC d/b/a IBT Bioservices to commercialize Dyadic-produced recombinant proteins through IBTaEUR(TM)s sales channels.

Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications today announced that it has entered into an original equipment manufacturer ("OEM") distribution agreement with Integrated Biotherapeutics, LLC, d/b/a IBT Bioservices ("IBT"), a life sciences reagent manufacturer and distributor serving global research markets. Through this collaboration, Dyadic-produced recombinant protein products will be commercialized through IBT's established sales channels, expanding market access and supporting Dyadic's objective of generating ongoing, product-based revenues.

The initial products expected to be offered under the agreement include recombinant DNase I and recombinant transferrin, with a focus on research-use-only ("RUO") applications. Dyadic expects to offer both human and bovine transferrin, along with additional cell culture–relevant recombinant proteins, as part of a broader and expanding product portfolio.

This relationship complements Dyadic's recent portfolio and manufacturing expansion initiatives and supports the Company's ability to commercialize a broader range of recombinant protein products across multiple end markets. By leveraging IBT's established commercial infrastructure, Dyadic can efficiently place products into the market while continuing to scale manufacturing capabilities and broaden its offerings over time.

"This agreement is a meaningful milestone for Dyadic," said Joe Hazelton, President and Chief Operating Officer of Dyadic. "It represents an important step in our transition from R&D-driven revenue toward commercial product sales, enabling Dyadic-produced products to reach the market through established global distribution channels. Agreements like this are central to our strategy as we focus on direct sales, OEM relationships, and other commercialization pathways to drive growth and build durable revenue streams over time."

In addition to OEM distribution, the collaboration provides flexibility for potential future expansion, which could include Dyadic supplying market-ready products for distribution or licensing production strains to support partner-led manufacturing, consistent with Dyadic's multi-channel commercialization approach.

Dyadic believes this agreement reflects continued progress in advancing from platform development to commercial execution and supports the Company's long-term objective of translating its technology and manufacturing capabilities into scalable revenue opportunities.

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon
COMTEX_478962092/2227/2026-05-11T22:20:28